Sign in
Active, not recruitingPhase 2

Platelet Rich Plasma Injections In Young And Old Human Subjects

Key facts

Who runs it
University of California, San Francisco
Where
San Francisco, United StatesSee the site
Trial code
Status
Active, not recruiting
Phase
Phase 2
People taking part
60 people, planned
Started
1 Jun 2024
Expected to end
16 Feb 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Platelet-Rich Plasma (PRP) Injections
  • Centrifuge
  • Control saline injection
Record updated
8 September 2026

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Grade 1-3 KL score will be recruited
  • Symptoms of knee osteoarthritis for at least 3 months before presentation in one knee
  • Have symptomatic complaints from osteoarthritis pain in no other joint affecting the hips, ankles or unaffected knee
  • Will be able to attend and perform physical therapy
  • English-speaking

Who cannot take part

  • Received injection therapy for knee osteoarthritis in the past 6 months
  • Have signs of concomitant osteoarthritis of 1 or more other major joints of the lower extremities that impair their daily activity level
  • Have underwent a previous knee surgery specifically for osteoarthritis or osteochondral defects less than 1 year before randomization (i.e. autograft or allograft surgery
  • High tibial osteotomy, partial knee replacement, patellar resurfacing), total knee replacement or existing surgical hardware in the knee
  • Patient taking Chemotherapy, need for regular prednisone or antiinflammatory used
  • History of septic arthritis
  • Patient with rheumatologic disease, automimmune disorder, immunocompromised status, active history of cancer
  • Uncontrolled illness, physical disability, or other contraindication to aerobic exercise training including, but not limited to:
  • Acute myocardial Infarction (within 5 days of any planned study procedure); ii. Unstable angina; iii. Uncontrolled arrhythmia causing symptoms or hemodynamic compromise; iv. Recurrent syncope; v. Active endocarditis; vi. Acute myocarditis or pericarditis; vii. Symptomatic severe aortic stenosis; viii. Uncontrolled heart failure; ix. Acute (within 3 months) pulmonary embolus or pulmonary infarction; x. Thrombosis of lower extremities; xi. Suspected dissecting aneurysm; xii. Uncontrolled asthma; xiii. Pulmonary edema; xiv. Room air desaturation at rest ≤85%; xv. Respiratory failure; xvi. Acute non-cardiopulmonary disorders that may affect exercise performance or be aggravated by exercise (ie infection, renal failure, thyrotoxicosis); and xvii. Mental impairment leading to inability to cooperate
  • Patient with platelet disorders, bleeding disorder
  • Patients will be excluded if:
  • Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study

Where in United States

  • University of CaliforniaSan Francisco, United States

About the trial

What the trial wants to find out

This is a randomized, double-blind, placebo-controlled phase 2 study with a secondary crossover phase at the end of the initial trial to ensure all subjects receive one PRP injection. The goal is to identify what proteins change in the blood following repeated intraarticular knee PRP injections in patients with knee osteoarthritis. The objective is to determine the protein changes resulting from a single autologous PRP injection (5 mL) in comparison to a normal saline control.

Read full original descriptionShow less

About 60 subjects will take part in this study by two age groups at UCSF into the following arms: Arm A: PRP injection; Arm B: normal saline injection control. The study aims to demonstrate what benefits PRP has on knee osteoarthritis and methods to best achieve biologic effects. Subjects with a diagnosis of knee osteoarthritis ages 18-45 and 46-70 years old presenting to a University Based sports medicine clinic will be screened for potential eligibility. Subjects who meet all qualifying requirements will be recruited from UCSF's orthopedic and primary care clinics.

Subjects will be on study for up to 26 weeks Screening: up to 14 days Treatment: injection of PRP or normal saline; subjects can cross over at week 12 to a PRP if originally in the control injection group Follow-up: 2 weeks post-baseline injection, 12 weeks postbaseline, (14 weeks if crossover patient), 26 weeks.

The 2 groups in the trial

  • Platelet-rich plasma (PRP)Treatment being tested

    A vacutainer vial containing 50 mL of peripheral blood will be processed immediately to create PRP using a previously optimized two-step centrifugation protocol viii. First, the whole blood will be centrifuged at 500 x g for 8 minutes at 4°C. The plasma will be collected above the buffy coat using a sterile pipette, placed into a separate sterile tube, and centrifuged a second time at 700 x g for 17 minutes at 12° C. The top 70% will be collected as the PPP and the bottom 30% will be resuspended as the PRP. PPP will be aliquoted into cryovials for storage at -80 °C. Approximately 6 mL of PRP will be produced from each 50 mL vial of whole blood. Five mL will be allocated for administration to patients and the remaining one mL will be aliquoted into cryovials for storage at -80 °C. The syringe containing PRP will be covered with Aluminum foil, such that the investigator cannot tell what fluid is to be injected.

    Treatment: Platelet-Rich Plasma (PRP) Injections and Centrifuge

  • Control saline injection (wait-list control)Placebo, for comparison

    A placebo injection of 6 mL of 0.9% saline will be prepared by the unblinded research assistant in an adjacent room. The syringed will be prepared in a 10 mL syringe and covered with Aluminum foil, such that the investigator performing the injection cannot tell if there is PRP or saline to be injected.

    Treatment: Platelet-Rich Plasma (PRP) Injections and Control saline injection

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Study of Platelet Rich Plasma (PRP) Injections With Symptomatic Knee Osteoarthritis for Biomarker Exploration in Young and Old Human Subjects
Record updated
8 September 2026